• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    11/30/22 12:32:32 PM ET
    $AGLE
    $BPTS
    $COSM
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Biophytis (NASDAQ:BPTS) stock moved upwards by 95.6% to $0.68 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 2.4 million shares, making up 1221.7% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares rose 63.62% to $0.2. As of 12:30 EST, this security is trading at a volume of 88.1 million shares, making up 3330.6% of its average full-day volume over the last 100 days. The company's market cap stands at $24.9 million.
    • Vapotherm (NYSE:VAPO) stock moved upwards by 29.48% to $0.85. Vapotherm's stock is trading at a volume of 789.8K shares as of 12:30 EST. This is 281.3% of its average full-day volume over the last 100 days. The company's market cap stands at $22.8 million.
    • Horizon Therapeutics (NASDAQ:HZNP) shares moved upwards by 26.87% to $99.93. As of 12:30 EST, this security is trading at a volume of 9.1 million shares, making up 353.3% of its average full-day volume over the last 100 days. The company's market cap stands at $22.6 billion.
    • OmniAb (NASDAQ:OABI) stock rose 20.07% to $3.41. As of 12:30 EST, this security is trading at a volume of 1.3 million shares, making up 45.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $392.0 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares moved upwards by 18.12% to $0.24. The market value of their outstanding shares is at $7.7 million.

    Losers

    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares fell 61.9% to $0.47 during Wednesday's regular session. As of 12:30 EST, Aeglea BioTherapeutics's stock is trading at a volume of 13.7 million, which is 999.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $28.6 million.
    • Cosmos Holdings (NASDAQ:COSM) stock decreased by 26.57% to $0.57. The current volume of 101.1 million shares is 273.5% of Cosmos Holdings's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $47.5 million.
    • OncoSec Medical (NASDAQ:ONCS) shares fell 25.98% to $2.85. OncoSec Medical's stock is trading at a volume of 3.5 million shares as of 12:30 EST. This is 515.8% of its average full-day volume over the last 100 days. The company's market cap stands at $5.1 million.
    • NanoVibronix (NASDAQ:NAOV) shares decreased by 20.4% to $0.4. As of 12:30 EST, NanoVibronix's stock is trading at a volume of 5.4 million, which is 452.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.1 million.
    • Science 37 Hldgs (NASDAQ:SNCE) stock declined by 14.62% to $0.57. Trading volume for Science 37 Hldgs's stock is 470.0K as of 12:30 EST. This is 154.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $66.4 million.
    • Statera BioPharma (NASDAQ:STAB) stock decreased by 13.35% to $0.12. As of 12:30 EST, this security is trading at a volume of 3.5 million shares, making up 107.5% of its average full-day volume over the last 100 days. The company's market cap stands at $6.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $BPTS
    $COSM
    $CRBP

    CompanyDatePrice TargetRatingAnalyst
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/26/2024$85.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

    NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long

    3/18/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

    CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum. Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy design

    3/11/26 1:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    SEC Filings

    View All

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form S-3 filed by Corbus Pharmaceuticals Holdings Inc.

    S-3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/11/26 5:06:17 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc.

    10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 4:16:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 7:43:03 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Smethurst Dominic sold $50,601 worth of shares (6,097 units at $8.30), decreasing direct ownership by 6% to 89,790 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/4/26 4:30:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $6,253 worth of shares (847 units at $7.38), decreasing direct ownership by 2% to 51,080 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:32:02 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Moran Sean F. sold $36,588 worth of shares (4,701 units at $7.78), decreasing direct ownership by 5% to 96,694 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:31:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Financials

    Live finance-specific insights

    View All

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AGLE
    $BPTS
    $COSM
    $CRBP
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces CEO Transition

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

    6/4/25 8:38:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care